A collaborative client-centered approach
Concept Life Science is a knowledge-based, science-led and customer-focused contract research and manufacturing organisation with world-leading expertise in the pharmaceutical, biotech and agrochemical industries. Our services are built on scientist-to-scientist communication, deep knowledge, flexibility and extensive in-house resources.
We are based across 5 research sites in the UK delivering discovery research as well as GMP, GLP and GCP-regulated work.
Whether it is delivering whole programs of research, or bespoke studies we deliver a collaborative client-centred approach.
Our services include discovery chemistry, specialist translational biology for immunology, oncology and neuroscience, biologics, biophysical assay services, ADMET & DMPK, bioanalysis, toxicology, histology, analytical services, including materials characterisation and physicochemical analysis, process research and development and GMP manufacturing.
Our leadership team
Dr Ben Cliff
Chief Executive OfficerDr Ben Cliff joined Concept Life Sciences in 2018 as VP Operations and has held both commercial and operational roles in the Company as the business has evolved. Most recently Ben has headed up operational delivery, supporting the business with strategic leadership across our service divisions to ensure quality execution and that the business is positioned for future growth. Ben brings a wealth of leadership experience in the CRO industry within the pharmaceutical, biotech, medical device and specialty chemical sector. His experience covers all aspects of the business including Operations, Sales and Marketing, Quality and Strategy.
Dr David Leese
Chief Operating OfficerDr David Leese is responsible for the day-to-day operational running of Concept Life Sciences, ensuring that the business has the resources required to allow it to build on the expertise of its scientists and continue to deliver to our clients’ needs. David has over 20 years of experience working in the CRO sector, starting his career at the bench, then leading multiple projects for a variety of clients.
We were originally formed in 2014, following the merger of a number of specialist CROs (Agenda 1 Analytical Services, Peakdale Molecular, CXR Biosciences).
Following further acquisition to expand our offering in 2017 (Aquila Biomedical) we were acquired by the precision instrument company, Spectris in 2018 and joined the Malvern Panalytical group within Spectris.
In 2023 following further investment by Limerston Capital we once again became an independent organisation.